The Latest Cardiac and Vascular News
Press release Malmö, September 2, 2020 Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period The Extraordinary General Meeting of Acarix AB (“Acarix” or the “Company”) resolved on 11 August 2020, subsequent to the board of directors resolution on 15 July 2020, to approve the board’s resolution for a […]
Acarix publishes prospectus in connection with rights issue of approximately SEK 56 million The Extraordinary General Meeting of Acarix AB (“Acarix” or the “Company”) resolved on 11 August 2020, subsequent to the board of directors proposal on 15 July 2020, to carry out a new share issue of a maximum of 86,156,738 shares with preferential […]
Announcement from Acarix’s extra general meeting The extra general meeting of Acarix AB (“Acarix” or the “Company“) was held today on 11 August 2020 and the following resolutions were passed by the meeting. Approval of rights issue The extra general meeting resolved, in accordance with the board of directors’ proposal, to approve the preferential rights […]
Press release (MAR) Malmö, May 14, 2020 Acarix AB (publ) publishes Interim Report, January – March 2020 Continued focus on strategic key priorities During the quarter we have kept focus on our priorities along with managing the impact from the global Covid-19 situation. We have been in continued dialogue with both the US Food and […]
Malmö, Sweden May 11, 2020 Last patient included in Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application. The exploratory clinical heart failure trial SEISMO was initiated in June 2018 to evaluate the possibility of developing an early heart […]
Press release Malmö, Sweden February 18, 2020 First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients Acarix AB (publ) today announced the initiation of the randomized, multi-center clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable coronary artery […]
Malmö, 9 October 2019 The subscription period in Acarix’ rights issue commence today The board of directors of Acarix AB (“Acarix” or the “Company”) resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 […]
Malmö, 25 September 2019 Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion The board of directors of Acarix AB (“Acarix” or the “Company”) has today, pursuant to the authorization granted by the extra general meeting on 16 August 2019, resolved to carry out a new share […]
Malmö August 5, 2019 CADScor®System – Significantly more effective than current practice Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients showing Acarix’s leading CADScor®System is more than three times as effective as current practice, implying clinical and economic advantages. “Strong clinical evidence is one of the key […]
Interim Report, January – September 2018 Malmö, November 14, 2018 Customer evaluation of CADScor®System compares favorably against existing methods “During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospitals clinical management team has now included the CADScor®System as method […]
